Tagcloud

ACE inhibitor, acetylcholinesterase inhibitor, aciclovir, acne, acute coronary syndrome, acute lymphoblastic leukaemia, ADHD, advanced prostate cancer, advanced renal cell carcinoma, advanced soft tissue sarcoma, adverse reaction, agomelatine, agoraphobia, alendronic acid, alfuzosin, algorithm, aliskiren, allergic rhinitis, allopurinol, alpha1-proteinase inhibitor, Alzheimer's, amantadine hydrochloride, ambrisentan, aminosalicylate, amlodipine, amoxicillin, anaemia, angina pectoris, anidulafungin, ankylosing spondylitis, anti-doping, anti-heparin, anti-human thymocyte immunoglobulin, antibacterial, antibiotic, anticoagulant, antidepressant, antineoplastic, antipsychotic, antiretroviral, antiretroviral therapy, anxiety, aromatase inhibitor, asthma, atazanavir, azacitidine, bacterial infections, BCG Vaccine, beclometasone, behaviour disorders, betamethasone, bevacizumab, bicalutamide, bipolar disorder, bisoprolol fumarate, bisphosphonates, black patients, bladder cancer, bowel cleansing, BPH, breakthrough pain, breast cancer, brinzolamide, bronchospasm, budesonide, bulimia nervosa, calcipotriol, calcium, candesartan, Candida albicans, candidiasis, carbetocin, carbidopa, cardiac insufficiency, cardiovascular disease, cefaclor, ceftriaxone, cefuroxime, cephalosporin, cetirizine, CHF, cholecalciferol, chronic constipation, chronic heart failure, Chronic Kidney Disease, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, chronic pain, chronic pulmonary infection, ciprofloxacin, citalopram hydrobromide, clarithromycin, clavulanic acid, clopidogrel, clotrimazole, clozapine, colorectal cancer, contraception, COPD, coronary artery disease, Crohn’s Disease, cystic fibrosis, dabigatran etexilate, daptomycin, darunavir, dasatinib, degarelix, dementia, depression, dermatophytes, dermatophytose, desogestrel, diabetes, diclofenac, dienogest, diphteria, discontinuations, domperidone, donepezil, doxazosin, doxycycline, drospirenone, duodenal ulcer, dyslipidaemia, eczema, eletriptan, emetogenic cancer chemotherapy, enalapril, endocarditis, entacapone, epigastric bloating, epilepsy, epirubicin, epoetin, ErbB2 (HR2) receptors, erythropoiesis-stimulating agents, esomeprazole, estradiol, ethinylestradiol, etravirine, everolimus, exemestane, faecal impaction, famciclovir, fentanyl, fesoterodine, fever, filgrastim, finasteride, fluconazole, fluoxetine, flurbiprofen, fluvastatin, folate, folic acid, follicular development stimulation, follicular lymphoma, follitropin alpha, fosprepitant, fungal infections, gabapentin, gastric cancer, gastric ulcer, gastroduodenal ulcer, gemcitabine, gestodene, gliclazide, glucosamine sulphate, gonorrhoea, GORD, growth failure, H1N1, hayfever, heart failure, heart rate, Helicobacter pylori, hepatic failure, hepatitis, hepatocellular carcinoma, herpes, hip or knee replacement surgery, hip osteoarthritis, HIV, hyaluronic acid, hydrochlorothiazide, Hylan G-F 20, hypercholesterolaemia, hyperlipidaemia, hyperphosphataemia, hypertension, hyperuricaemia, hypoactive sexual desire disorder, ibritumomab, ibuprofen, IGF-1 deficiency, IMB, immunosuppression, indacaterol, indapamide, infections, inflammation, influenza, insomnia, interferon beta-1a, iobetasol, IOP, ipatropium bromide, irinotecan, Irish Sports Council, ischaemic stroke, isotretinoin, ivabradine, Kaposi's sarcoma, kidney cancer, kidney disease, knee osteoarthritis, lacosamide, lamotrigine, lansoprazole, lapatinib, laropiprant, lenalidomide, lercanidipine, leuprorelin acetate, levodopa, levonorgestrel, liraglutide, lisinopril, losartan, lutropin alpha, Lyme disease, macrogol, magnesium, mania, maraviroc, mecasermin, melatonergic, melatonin, meloxicam, memantine, mesalazine, metastatic colorectal carcinoma, metformin, methadone, methylnaltrexone bromide, methylphenidate hydrochloride, mexiletine hydrochloride, micafungin, migraine, mirtazapine, mixed dyslipidaemia, moxifloxacin, multiple myeloma, multiple sclerosis, muscular disorders, myelodysplastic syndromes, myocardial infarction, naloxone, naratriptan, nasal congestion, nausea, nebivolol, nephropathy, neural tube defects, neutropenia, NICE guidelines, nicotine, nicotinic acid, nilotinib, NSCLC, nutrition, OCD, ocular hypertension, olanzapine, olmesartan, omeprazole, ondensetron, open angle glaucoma, opioid addiction, opioid analgesic, opioid-induced constipation, oseltamivir, osteoarthritis, osteonecrosis of the jaw, osteoporosis, otitis, ovarian cancer, overactive bladder syndrome, oxycodone, paclitaxel, pain, pancreatic cancer, pancreatic exocrine insufficiency, pancreatin, panic disorder, panitumumab, pantoprazole, paracetamol, Parkinson’s, partial-onset seizures, patch, pemetrexed, peptic ulcer, perindopril, peripheral arterial disease, peripheral neuropathic pain, pertussis, piperacillin, Pityriasis versicolor, poliomyelitis, post transplantation hyperlipidaemia, post-operative pain, post-traumatic stress disorder, PPIs, pramipexole, pravastatin, pregnancy, pricing policy, primary hypercholesterolaemia, probiotics, prostate cancer, protamine sulphate, Pseudomonas aeruginosa, psoriasis, psychotic disorders, pulmonary arterial hypertension, pulmonary embolism, quetiapine, raltegravir, ramipril, ranolazine, rasagiline, recombinant IGF-1, reflux oesophagitis, renal disease, renin inhibitor, Restless Legs Syndrome, rheumatoid arthritis, ribavirin, ringworm, risedronate sodium, risperidone, rivaroxaban, rivastigmine, romiplostim, ropinirole, rosacea, RTI, S. aureus, salbutamol, sarcoma, saxagliptin, schizophrenia, SCLC, sertraline, sevelamer carbonate, severe pain, simvastatin, sitagliptin, smoking cessation, sodium alginate, solide organ transplantation, sorafenib, sore throat, spasticity, spinal cord injury, sport, sprain, statins, stroke, strontium ranelate, suicide, systemic embolisation, telmisartan, temsirolimus, terbinafine, testosterone, tetanus, thalidomide, thrombocytopenic purpura, thrush, tibolone, timolol, tinea, tiotropium, tipranavir, tizanidine, tobramycin, tocilizumab, topotecan, trabectedin, tramadol, Trichophyton, trimethoprim, trospium chloride, ustekinumab, UTI, vaccine, valaciclovir, valproate, valsartan, varenicline, venlafaxine, venous thromboembolism, venous thrombosis, vildagliptin, vinorelbine, vitamin D, vomiting, WADA, warfarin, wound, zanamivir, zoledronic acid, Zollinger-Ellison syndrome

MIMS Ireland: New Clinical Evidence

All entries for New Clinical Evidence

Seroquel XR prevents recurrence of BD

01 March 2010

Seroquel XR (quetiapine) Approved for Maintenance Treatment to Prevent Recurrence of Bipolar Disorder AstraZeneca announced that once-daily Seroquel XR (extended-release tablets) has been approved in Ireland for the prevention of recurrence of bipolar disorder (BD) in patients whose manic, mixed... Read more

Reduced duration of common winter infections in the elderly with Actimel

01 February 2010

Probiotics or have long been the focus of considerable research to demonstrate their potential health benefits including: preventing C. difficile infection, antibiotic-associated diarrhoea and infant eczema.... Read more

Micardis approved to reduce cardiovascular risk

01 February 2010

Boehringer Ingelheim wish to announce that the European Commission has approved Micardis (telmisartan) for the reduction of cardiovascular morbidity in patients with: I. manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or, II. type... Read more

Mirapexin prolonged-release, new once daily tablet for PD

01 February 2010

Boehringer Ingelheim wish to announce that new Mirapexin (pramipexole) prolonged-release, once daily tablet has been granted marketing authorisation by the European Commission in all EU/EEA countries for the treatment of early and advanced idiopathic Parkinson’s disease (PD).... Read more

First melatonergic antidepressant Valdoxan showed to have long term efficacy in preventing relapse

01 October 2009

Servier wish to announce that the melatonergic agonist Valdoxan (agomelatine) has been approved for the treatment of major depressive episodes.... Read more

Procorolan reduces MI in angina patients

01 October 2009

The results of a newly published sub-study of the BEAUTIFUL trial* in patients with limiting angina were announced recently at the ESC in Barcelona, Spain.... Read more

Nexium IV licensed to reduce the risk of peptic ulcer rebleeding

01 August 2009

Nexium IV (esomeprazole) has been approved in Ireland for prevention of rebleeding following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers. Currently, it is the only proton pump inhibitor (PPI) to be licensed in Ireland for this condition. Nexium... Read more

Avastin in advanced breast cancer - RIBBON-1

01 May 2009

New phase III study of Avastin in advanced breast cancer meets its primary endpoint of increasing Progression Free Survival.... Read more

Results from TEAM trial with Aromasin

01 May 2009

Pfizer wish to announce results from a first planned analysis of the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicentre) trial conducted in postmenopausal women with hormone sensitive early breast cancer.... Read more

Seroquel XR approved for treatment of bipolar disorder

01 April 2009

Seroquel XR approved in Ireland for new indications for the treatment of bipolar disorder.... Read more

Epilim approved for treatment and prevention of mania

01 April 2009

Epilim prolonged release approved for the treatment and prevention of mania associated with bipolar disorders... Read more

Vimpat Approved in Europe

02 March 2009

• Improved seizure control when added to other antiepileptic drugs (AEDs) (1) • High long-term retention rate • A dual mode of action... Read more

RECORD trials with Xarelto

05 January 2009

Xarelto Reduces Symptomatic VTE and Death Following Knee or Hip Replacement Surgery Compared to Enoxaparin.... Read more

Exforge-based therapy in difficult-to-treat, black patients

01 December 2008

Significant blood pressure reductions is obtained in difficult-to-treat, black patients receiving Exforge-based therapy.... Read more

Rasilez ASPIRE HIGHER

01 December 2008

Rasilez ASPIRE HIGHER cardio-renal outcomes program expands to 35,000 patients in 14 trials... Read more

Lexapro compared with duloxetine

escitalopram, SSRI, Lundbeck, Lexapro | 01 November 2008

Lexapro offers greater efficacy and tolerability compared with duloxetine in the treatment of major depressive disorder (1)... Read more

Once-yearly Aclasta new approval

01 November 2008

Once-yearly Aclasta approved in EU to treat osteoporosis in men and to reduce risk of new fractures following hip fracture both in men and postmenopausal women.... Read more

BEAUTIFUL: Cardiovascular benefits of Procoralan

01 October 2008

The results of the BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have been recently announced in Munich, Germany.... Read more

ADAGIO results on PD progression and the use of Azilect

01 October 2008

Lundbeck's partner Teva Pharmaceutical Industries Ltd. wish to announce the results of the ADAGIO (Attenuation of Disease progression with Azilect® GIven Once-daily) study – one of the largest studies ever conducted in Parkinson's disease (PD), and the first prospective trial... Read more

New data on Ebixa efficacy in moderate to severe AD

01 September 2008

New data analysis shows that memantine (Ebixa) is effective in treating and preventing specific behavioural symptoms associated with moderate to severe Alzheimer's disease (AD), with benefits seen for agitation/aggression and delusions at week 12 and 24.... Read more

Coversyl protects hypertensive patients against new-onset diabetes

01 June 2008

A new analysis of data from the landmark Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA) published in Diabetes Care has identified the major predictors of new-onset diabetes (NOD) in patients with hypertension(1).... Read more

Second phase III study of Avastin

01 May 2008

Second phase III study of Avastin in 1st line metastatic breast cancer meets its primary endpoint - Roche has recently announced that a phase III study in metastatic breast cancer investigating Avastin (bevacizumab) in combination with docetaxel chemotherapy compared to... Read more

New review highlights Femara benefits

01 May 2008

New review highlights Femara benefits in terms of reduction of the risk of distant relapse in women with hormone-sensitive breast cancer - A new review underlining the significance of distant metastases in breast cancer outcomes highlights the benefits of aromatase... Read more

Seroquel XR once-daily prolonged tablets

01 May 2008

Seroquel XR once-daily prolonged tablets for the treatment of schizophrenia - AstraZeneca announced last month the Irish launch of Seroquel XR (quetiapine fumarate) Prolonged-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients.... Read more

Nilotinib Is Highly Active and Safe

01 May 2008

Nilotinib Is Highly Active and Safe in Chronic Myelogenous Leukaemia Patients with Imatinib-Resistance or Intolerance - New data demonstrated the efficacy and tolerability of Tasigna (nilotinib) in the treatment of Chronic myelogenous leukaemia (CML) patients with Imatinib-Resistance or Intolerance for... Read more

Zevalin Receives Positive CHMP Opinion

01 May 2008

Zevalin Receives Positive CHMP Opinion in Europe for First-Line Consolidation Treatment - Bayer Schering Pharma AG has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy after... Read more

Yondelis available for advanced soft tissue sarcoma

01 April 2008

PharmaMar is pleased to announce the availability of Yondelis in Ireland. Yondelis (trabectedin) is an antineoplastic agent that is indicated for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited... Read more

Protelos new data in younger women

01 March 2008

Major anti-fracture efficacy in young post-menopausal osteoporotic women New data from the Spinal Osteoporosis Therapeutic Intervention (SOTI) trial showed that Protelos has significant vertebral anti-fracture efficacy in young postmenopausal osteoporotic women, confirming the benefit of Protelos, whatever the age of... Read more

Nebivolol (Nebilet) is Now Licensed for the Treatment of Hypertension in the USA

01 February 2008

In New York on December 18th 2007, Forest Laboratories, Inc., and Mylan Inc., announced that the novel beta blocker nebivolol (Bystolic) is now licensed for the treatment of hypertension. Nebivolol, trade name Nebilet in Ireland, is already approved and successfully... Read more

Avastin approved in Europe for first-line treatment of patients with advanced kidney cancer

01 February 2008

Roche Products (Ireland) Ltd., wish to announce that Avastin (bevacizumab) is approved in EU for the first-line treatment of patients with renal cell carcinoma, the most common form of advanced kidney cancer. Treatment options for patients with kidney cancer are... Read more

Efficacy and Tolerability of new Once daily Exelon Transdermal Patch

01 February 2008

Novartis Ireland wish to announce the launch of once daily Exelon transdermal patch, for the first line treatment of mild to moderately severe Alzheimer’s dementia (AD).... Read more

Aclasta Once yearly for Treatment of Postmenopausal Osteoporosis

01 February 2008

Novartis Ireland are delighted to announce the availability of Aclasta (zoledronic acid) for the treatment of postmenopausal osteoporosis. Bisphosphonates, the most commonly used treatment for established osteoporosis, inhibit osteoclast-mediated bone resorption and reduce the risk of fracture. However, adherence to... Read more

Efexor XL Approved for the Treatment of Panic Disorder

01 February 2008

Wyeth is pleased to announce the launch of Efexor XL 37.5mg for use in Panic Disorder, with or without agoraphobia. Panic disorder is characterised by recurrent, unexpected panic attacks; i.e., a discrete period of intense fear or discomfort in the... Read more

Mircera once every four weeks for dialysis patients

01 February 2008

Pivotal Mircera study first to convert dialysis patients from frequent dosing directly to once every four weeks. A pivotal study published in the Lancet has shown that dialysis patients can be effectively switched from frequently dosed anaemia drugs to an... Read more

Nexavar New Indication

01 January 2008

Nexavar Approved in Europe for the Treatment of Patients with Hepatocellular Carcinoma Bayer Schering Pharma wish to announce that Nexavar (sorafenib) has been approved in Europe for the treatment of Hepatocellular Carcinoma (HCC).... Read more

New Data Supporting Efficacy of Spiriva Respimat

01 January 2008

Data Support similar Efficacy in COPD Patients of Tiotropium Administered via the Respimat Soft MistTM Inhaler compared with HandiHaler - Boehringer Ingelheim and Pfizer Healthcare wish to announce the introduction of Spiriva Respimat which uses Respimat Soft Mist Inhaler as... Read more